Inflammatory Bowel Disease

Discussing the latest advances in Crohn’s disease and ulcerative colitis

Share this:
November 9, 2015

Highlights of ACG’s Annual Scientific Meeting 2015

By Kanaaz Pereira
For five days, from October 16 to October 21, 2015, renowned experts in the field of gastroenterology offered clinical insights and real-world perspectives at the American College of Gastroenterology's Annual Scientific Meeting in Hawaii. Dr. Sunanda Kane, M.D., summarizes some of the bigger studies that were presented at the meeting, including key research done on
    • 6-mercaptopurine (6-MP), (Purinethol)
    • Azathioprine, (Imuran)
    • Infliximab, (Remicade)
    • Ustekinumab, (Stelara)
    • Ozanimod

Learn more about the ACG meeting here.

For more information about IBD, visit

Dr. Kane is a gastroenterologist at Mayo Clinic.

Tags: American College of Gastroenterology, Events, IBD, News Alerts, Sunanda Kane

Allergic to sulfur drugs and been maintained with 6-MP. Has worked for me. However, I have also done Remicade and Humira. I have always relapsed at some point after stopping treatments. I have always had a severe case of Crohn’s and every side effect to go with it. I suffer as much from side effects as from bowel degeneration. So I’m not sure if I’ve ever really had complete remission.

Please login or register to post a reply.
Contact Us · Privacy Policy